Skip to main content
Fig. 2 | Cardio-Oncology

Fig. 2

From: Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

Fig. 2

The patient with concomitant cardiovascular disease receiving Ibrutinib are more likely to develop atrial fibrillation. This owes to both underlying cardiovascular condition related changes as well as the disruption in molecular signaling. We propose that the patients should be screened and managed for pre-existing cardiovascular conditions prior to initiating Ibrutinib. Atrial fibrillation can be asymptomatic and associated with increased risk of thromboembolic events. And, therefore, we recommend rhythm screening for patients with cardiovascular conditions

Back to article page